US approves highly anticipated Eli Lilly weight loss drug

The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful—and lucrative—new obesity medicines.

Oncology & Cancer

A potential new marker for personalized breast cancer therapy

A new study from the University of Southampton has discovered that "crown-like structures" surrounding breast tumors in overweight and obese patients could hinder their response to therapy. The findings of this study could ...


Quinn on Nutrition: Do vitamin patches work?

I sometimes consult with overweight patients who are considering bariatric (weight loss) surgery. For some individuals, the need to take specific vitamin and mineral supplements for the rest of their lives is not an easy ...


Heart patients need more help to lose weight

Weight loss is given insufficient priority in the management of heart patients despite the benefits, according to a study published today in European Heart Journal—Quality of Care and Clinical Outcomes.

Oncology & Cancer

Study finds dosing strategy may affect immunotherapy outcomes

Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center.

page 1 from 8